Stifel Downgrades Biogen(BIIB.US) to Hold Rating, Cuts Target Price to $175

Futu News21minutes ago · Ratings

Stifel Downgrades Biogen to Hold From Buy, Adjusts Price Target to $175 From $275

MT Newswires18:42 · Ratings

Palantir, MicroStrategy Could Be Added to Nasdaq 100 Friday. Moderna, Super Micro Could Be Dropped.

BarronsDec 14 00:46

Biogen Stock Touches 52-week Low at $153.55 Amid Challenges

InvestingDec 13 22:36

Biogen ALS Drug Needs to Be Covered by MA Plans, CMS Says

Seeking AlphaDec 13 06:37

Is Biogen Inc.'s (NASDAQ:BIIB) Stock Price Struggling As A Result Of Its Mixed Financials?

Yahoo FinanceDec 13 00:59